| Market Cap | 107.66M | P/E | - | EPS this Y | 12.50% | Ern Qtrly Grth | - |
| Income | -117.5M | Forward P/E | -0.74 | EPS next Y | 1.40% | 50D Avg Chg | -35.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -61.00% |
| Dividend | N/A | Price/Book | 0.31 | EPS next 5Y | - | 52W High Chg | -88.00% |
| Recommedations | 1.70 | Quick Ratio | 10.64 | Shares Outstanding | 70.43M | 52W Low Chg | 15.00% |
| Insider Own | 5.16% | ROA | -18.54% | Shares Float | 22.38M | Beta | 0.71 |
| Inst Own | 72.27% | ROE | -36.41% | Shares Shorted/Prior | 5.57M/4.18M | Price | 2.20 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 480,701 | Target Price | 19.25 |
| Oper. Margin | - | Earnings Date | May 9 | Volume | 534,956 | Change | -2.65% |
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Needham | Buy | Apr 10, 24 |
| Canaccord Genuity | Buy | Mar 26, 24 |
| HC Wainwright & Co. | Buy | Mar 25, 24 |
| Mizuho | Buy | Mar 22, 24 |
| Needham | Buy | Mar 22, 24 |
| HC Wainwright & Co. | Buy | Mar 22, 24 |
| Raymond James | Outperform | Mar 22, 24 |
| Mizuho | Buy | Mar 5, 24 |
| HC Wainwright & Co. | Buy | Jan 16, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Trager James | Chief Scientific Off.. Chief Scientific Officer | Jan 13 | Sell | 5.49 | 1,115 | 6,121 | 98,557 | 01/18/23 |
| Shook David | Chief Medical Office.. Chief Medical Officer | Jan 13 | Sell | 5.49 | 175 | 961 | 60,302 | 01/18/23 |
| Mahmood Nadir | See Remarks See Remarks | Jan 13 | Sell | 5.49 | 1,122 | 6,160 | 84,302 | 01/18/23 |
| HASTINGS PAUL J | Chief Executive Offi.. Chief Executive Officer | Jan 13 | Sell | 5.49 | 3,691 | 20,264 | 313,106 | 01/18/23 |
| Hager Alicia J. | Chief Legal Officer Chief Legal Officer | Jan 13 | Sell | 5.49 | 1,103 | 6,055 | 57,197 | 01/18/23 |
| Brandenberger Ralph | Chief Technical Offi.. Chief Technical Officer | Jan 13 | Sell | 5.49 | 491 | 2,696 | 28,309 | 01/18/23 |
| Trager James | Chief Scientific Off.. Chief Scientific Officer | Aug 15 | Option | 3.89 | 5,000 | 19,450 | 67,172 | 08/17/22 |
| Trager James | Chief Scientific Off.. Chief Scientific Officer | Aug 15 | Sell | 17.53 | 5,000 | 87,650 | 62,172 | 08/17/22 |
| Brandenberger Ralph | Chief Technical Offi.. Chief Technical Officer | Aug 15 | Option | 3.89 | 11,000 | 42,790 | 18,800 | 08/17/22 |
| Brandenberger Ralph | Chief Technical Offi.. Chief Technical Officer | Aug 15 | Sell | 17.64 | 11,000 | 194,040 | 7,800 | 08/17/22 |
| Mahmood Nadir | See Remarks See Remarks | Aug 15 | Option | 3.89 | 7,500 | 29,175 | 53,588 | 08/17/22 |
| Mahmood Nadir | See Remarks See Remarks | Aug 15 | Sell | 18.03 | 7,500 | 135,225 | 46,088 | 08/17/22 |
| Brandenberger Ralph | Chief Technical Offi.. Chief Technical Officer | Aug 08 | Option | 3.02 | 11,593 | 35,011 | 19,393 | 08/10/22 |
| Brandenberger Ralph | Chief Technical Offi.. Chief Technical Officer | Aug 08 | Sell | 15.51 | 11,593 | 179,807 | 7,800 | 08/10/22 |
| Mahmood Nadir | See Remarks See Remarks | Aug 08 | Option | 3.89 | 7,500 | 29,175 | 53,588 | 08/10/22 |
| Mahmood Nadir | See Remarks See Remarks | Aug 08 | Sell | 15.32 | 7,500 | 114,900 | 46,088 | 08/10/22 |
| Brandenberger Ralph | Chief Technical Offi.. Chief Technical Officer | Jul 25 | Option | 0.41 | 3,000 | 1,230 | 10,800 | 07/26/22 |
| Brandenberger Ralph | Chief Technical Offi.. Chief Technical Officer | Jul 25 | Sell | 13.41 | 3,000 | 40,230 | 7,800 | 07/26/22 |
| Mahmood Nadir | See Remarks See Remarks | Jul 25 | Option | 3.89 | 7,500 | 29,175 | 53,588 | 07/26/22 |
| Mahmood Nadir | See Remarks See Remarks | Jul 25 | Sell | 13.4 | 7,500 | 100,500 | 46,088 | 07/26/22 |
| George Simeon | Director Director | Apr 28 | Buy | 15 | 1,333,333 | 19,999,995 | 666,666 | 04/29/22 |